Hot biotech stocks to watch right now as cancer treatments make headlines in 2021.: Just one day after Merck's (NYSE:MRK) blockbuster FDA approval news, Bristol-Myers Squibb (NYSE:BMY) added more fuel to the fire. Cancer treatments have remained a hotbed for biotech companies. Now the R&D from years past seems to have begun paying off. Wednesday morning Bristol-Myers reported its second-quarter earnings. After dissecting the data, there are several significant things to take away from these results. First, the biotech company is back to growth. The company reported an increase of 16% year-over-year in quarterly revenue with $11.7 billion.
As its name suggests, venture firm Pillar VC is focused on building "pillar" companies in Boston and across the Northeast.
Eliem Therapeutics, a clinical stage biotech company generating therapies for pain, depression and other nervous-system related conditions, has filed to go public via an IPO. The company's filing with the U.S. Securities and Exchange Commission comes on the heels of two rounds of private funding already this year tallying $140 million, including a $60 million Series B round in May. The Redmond, Wash.-based company was founded in 2019 and plans to list on the Nasdaq under the symbol ELYM. It aims to raise up to $80 million with the IPO.
Summary List PlacementInvestors keep pouring cash into biotech, and the surge just helped investment firm Perceptive Advisors raise a new venture fund that's more than double the size of its previous one. Perceptive, which is based in New York, raised $515 million for its second Perceptive Xontogeny Fund, the firm told Insider. Perceptive raised $210 million for its first Xontogeny Fund in 2019. The fund's name references the accelerator Perceptive has a stake in, Xontogeny, led by biotech veteran Chris Garabedian.
China Money Podcast: Robotics, Biotech And Electric Vehicle Startups Clear Funding Hurdles - China Money Network
In this episode of China Money Podcast, listen to all the news headlines in the China venture investment and tech sector for the week ending April 16. We are at the midpoint of the month of April, and we recorded 58 different startup, growth stage, and pre-IPO investment deals closing in the past 5 days [...] China Money Podcast: Robotics, Biotech And Electric Vehicle Startups Clear Funding Hurdles comes from China Money Network: Primary Data for China's Primary Markets! All Rights Reserved.
REDWOOD CITY, Calif., April 15, 2021 /PRNewswire/ -- Trace Genomics announces the appointment of Dr. Robert (Robb) Fraley to its board of directors. Dr. Fraley, who served for nearly 40 years as chief technology officer at Monsanto and helped develop the first genetically modified seed,...
SAN FRANCISCO, April 14, 2021 /PRNewswire/ -- Benchling, the leading life sciences R&D cloud, has raised $200 million in Series E funding led by Sequoia Capital Global Equities and joined by Altimeter Capital, Byers Capital and Elad Gil. Existing investors participated, including Thrive...
New funding: Outpace Bio raised a $30 million Series A investment round to design custom cell and gene-based therapies. The science: Founded in November, the Seattle startup is developing software and hardware to manipulate how cells interact with diseases. Its initial work is focused on T cell therapies that fight solid tumors. Partnership with Lyell: The 18-person company also announced a partnership with San Francisco startup Lyell Immunopharma to pursue commercialization of a potential immune cell therapy for cancer treatment. Investors: ARTIS Ventures and Lyell led the round.
Summary List PlacementBiotech investors are flooding into the mental health and neuroscience fields, and RA Capital is the latest to get in on the trend. The venture capital firm launched Eliem Therapeutics on Thursday, after combining two biotechs it had been incubating for several years. Eliem raised a $39 million Series A extension round at a $145 million valuation, according to three sources, who asked not to be identified as they were not authorized to discuss financials publicly. Eliem now has $80 million in capital, which is expected to fund it through 2022, according to an investor at RA Capital.
NANJING, China, March 24, 2021 /PRNewswire/ -- Bioheng Biotech Co., Ltd, a clinical-stage biotechnology company dedicated on developing novel cellular immunotherapy for cancer, today announced that it had secured $80 million in Series B Financing. The Series B was co-led by GL Ventures,...